CA9


Also found in: Acronyms.

CA9

A gene on chromosome 9p12 that encodes a carbonic anhydrase, a zinc metalloenzyme that catalyses the reversible hydration of carbon dioxide. Carbonic anhydrases participate various biological processes, including respiration, calcification, maintaining acid-base balance, bone resorption and producing aqueous humour, cerebrospinal fluid, saliva and gastric acid. CA9 is a transmembrane protein and the only known tumour-associated carbonic anhydrase isoenzyme, and may be involved in cell proliferation and transformation.
 
Molecular pathology
CA9 is expressed in all clear-cell type renal cell carcinomas, but is not expressed in normal kidney or most other normal organs.
Mentioned in ?
References in periodicals archive ?
We found that the CA9 mRNA expression of BCSCs was gradually enhanced after 6-h alkalinization compared to that of non-alkalinized BCSCs (Figure 1B).
Nevertheless, this study demonstrated that the increase of CA9 mRNA and CAe activity was an earlier response to the alkaline pHe compared to the increase HIF1[alpha] mRNA and protein.
Diferencias de medias en los Conceptos de la prueba de Abril GE41 y GC4 Cuarto periodo Conceptos GC3 GE3 MC3 ME3 DC3 DE3 t CA1 33 33 0,697 0,667 0,467 0,479 0,26 CA2 33 33 0,424 0,576 0,502 0,502 -1,226 CA3 33 33 0,424 0,636 0,502 0,489 -1,74 CA4 33 33 0,545 0,545 0,506 0,506 0 CA5 33 33 0,242 0,333 0,435 0,479 -0,807 CA6 33 33 0,333 0,606 0,479 0,496 -2,272 CA7 33 33 0,03 * 0,212 0,174 0,415 -2,32 CAS 33 33 0,303 0,576 0,467 0,502 -2,286 CA9 33 33 0,394 0,485 0,496 0,508 -0,736 CA10 33 33 0,303 0,333 0,467 0,479 -0,26 Conceptos p COHEN CA1 0,795 0,064 CA2 0,225 -0,302 CA3 0,087 -0,428 CA4 1 0 CA5 0,423 -0,199 CA6 0,026 -0,559 CA7 0,025 -0,571 CAS 0,026 -0,563 CA9 0,465 -0,181 CA10 0,795 -0,064 Tabla 10.
Diferencias de medias en los Conceptos de la prueba de Abril GE42 y GC42 Conceptos GC42 GE42 MC42 ME42 DC42 DE42 t CA1 21 21 0,524 0,810 0,512 0,402 -2,011 CA2 21 21 0,476 0,571 0,512 0,507 -0,606 CA3 21 21 0,476 0,524 0,512 0,512 -0,302 CA4 21 21 0,619 0,619 0,498 0,498 0,000 CA5 21 21 0,143 0,286 0,359 0,463 -1,118 CA6 21 21 0,667 0,524 0,483 0,512 0,930 CA7 21 21 0,190 0,190 0,402 0,402 0,000 CAS 21 21 0,429 0,476 0,507 0,512 -0,303 CA9 21 21 0,429 0,476 0,507 0,512 -0,303 CA10 21 21 0,190 0,333 0,402 0,483 -1,041 Conceptos p COHEN CA1 0,051 -0,621 CA2 0,548 -0,187 CA3 0,765 -0,093 CA4 1,000 0,000 CA5 0,271 -0,345 CA6 0,358 0,287 CA7 1,000 0,000 CAS 0,764 -0,093 CA9 0,764 -0,093 CA10 0,304 -0,321
Conclusions: We noted that there was no relationship between CA9 and HIF-l[alpha] expression with other prognostic clinicopathologic features.
CA9 ve HIF-1[alpha] immtinoreaktivite duzeyleri dort grupta siniflandirildi: CA9 icin %0, %1-25, %26-50, >%50; HIF-l[alpha] icin [less than or equal to] 1-10, %11-50, %51-80, >%80.
Plaque-reduction assay (PFU), cytopathogenic effect (CPE), immunoassay (ELISA): The antiviral activity of Bioaron C[R] was measured with plaque-reduction assays (Cooper 1955) in plaque forming units (PFU) for FluA (H1N1, H3N2), FluB (Yamagatal, Beiying) and Para 3, RSV, HRV 14, CA9 or with analyses of a cytopathogenic effect (CPE) for Adeno 5.
The quantification of the antiviral activity was either carried out by analysing the number of plaques (PFU: FluA, FluB, Para 3, HRV 14, CA9, RSV), the lesions of viral CPE (Adeno 5) and the amount of viral proteins detected in ELISA (Adeno 5).
72) The pattern of CA9 expression in PRCC, which is patchy and often perinecrotic when present, is usually easily distinguished from the diffuse membranous pattern seen in CCRCC (39,42,73,74) (Figure 2, D).
For all virus strains with the exception of CA9 positive controls were included in a single concentration close to their [IC.
101) Immunolabeling-based studies have reported overexpression of CTNNB1, (100) INHA, MUC6, ENO2, MUC1, (102) ANXA1, (103) CA9, (104) and SPARCL1 (105) in some of these less common exocrine neoplasms.